FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310117770> ?p ?o ?g. }

• W4310117770 endingPage "1600" @default.
• W4310117770 startingPage "1598" @default.
• W4310117770 abstract "Background: Only 18-44% of adult patients with R/R B-Cell ALL achieve remission with median overall survival (OS) of 2 to 6 months after salvage chemotherapy. Blinatumomab and inotuzumab ozogamicin have been approved for their higher response rate, though outcome remains unsatisfied with a median OS of 7.7 months. Thus, adult R/R B-cell ALL has a highly unmet medical need for new and more effective treatment options. CNCT19 (inaticabtagene autoleucel) is an autologous CD19-specific chimeric antigen receptor (CAR) T-cell product. The patent protected CAR structure of CNCT19 contains a unique CD19 scFv, HI19a, which is different from commonly used FMC63. Together with using 4-1BB co-stimulatory domain in the CAR structure, CNCT19 is expected to reduce the severity of treatment-associated cytokine release syndrome (CRS) and neurological toxicities (NT) while maintaining a stronger and longer durable anti-tumor effect. CNCT19 has been granted Breakthrough Therapy Designation by China National Medical Products Administration and Orphan Drug Designation by the U.S. FDA for the treatment of B-cell ALL. Methods: The trial of CNCT19 in adult Chinese patients with R/R B-cell ALL (NCT04684147) is a single-arm, open-label pivotal study conducted at 10 centers in China. Patients underwent leukopheresis to obtain cells for CNCT19 manufacturing. CNCT19 was infused 2 to 14 days after lymphodepletion with cyclophosphamide and fludarabine. A single infusion of CNCT19 at a target dose of 0.5 × 108 (±20%) CAR+ viable T cells was administered. The primary endpoint was the overall complete response rate (OCR) of complete response (CR) and CR with incomplete hematological recovery (CRi) within 3 months and at the end of Month 3 after CNCT19 infusion by central assessment. The minimal residual disease (MRD) negative rate, duration of remission, relapse-free survival, and OS were assessed as secondary endpoints. Results Patients Of 53 patients enrolled and underwent leukopheresis, 36 were eligible for lymphodepletion and received CNCT19 treatment. CNCT19 was manufactured using serum-free culture system at Juventas GMP facility and no manufacture failure was reported. All 36 patients diagnosed with B-cell ALL were refractory (83.3%) and relapsed (16.7%) to multiple lines of prior therapy (83% patients had received 2 or more therapies). Twenty-one patients (58.3%) had more than 50% blasts in the bone marrow. Seven patients (19.4%) received hematopoietic stem cell transplantation (HSCT). Notably, 22 patients (61%) had high-risk cytogenetic abnormalities and somatic genetic mutations, including Ph+, TP53, 11q23/MLL, IKZF1, and E2A-PBX1 alteration. Efficacy (Table 1) OCR within 3 Months: Among the 36 patients, 31 (86.1%) had reached MRD-negative OCR within 3 months after CNCT19 infusion, including 24 patients (66.7%) with CR and 7 (19.4%) with CRi. The median duration of remission and OS have not been reached. OCR at the end of Month 3: Of the 32 patients who were evaluable at the end of Month 3 after CNCT19 infusion, 21 patients (65.6%) remained on CR (50%) or CRi (15.6%). These patients had sustained long-term remission regardless of whether subsequent allo-HSCT treatment was done or not. Among them, 6 patients were in ongoing remission for over 12 months, and the longest duration of remission without any other subsequent anti-cancer therapy has surpassed 15 months with persistently detectable CNCT19 in blood. (Figure 1) Safety The most common CNCT19-related adverse events (AEs) were CRS and NT and there were 3 cases of Grade ≥ 3 CRS (n=3, 8.3%) and 3 cases of Grade ≥ 3 NT (n=3, 8.3%). Following CNCT19 infusion, all the patients recovered. No death cases were reported due to CRS or NT. Conclusions CNCT19 CAR-T cell therapy achieved a high rate of MRD-negative complete remission in adult patients with R/R B-cell ALL. The OCR within 3 Months and OCR at the end of Month 3 were 86.1% and 65.6%, respectively. The patients remaining on the CR/CRi at the end of Month 3 had a long duration of remission. While CAR T-cell treatment-associated AEs were reported in most patients, a comprehensive medical team to monitor and manage the patients significantly decreased the severity of treatment-related AEs. Thus, with its distinct CAR structure containing a unique CD19 scFv (HI19a), CNCT19 provides effective treatment with potential long-term clinical benefits for adult patients with R/R B-cell ALL. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal" @default.
• W4310117770 created "2022-11-30" @default.
• W4310117770 creator A5002329460 @default.
• W4310117770 creator A5018863416 @default.
• W4310117770 creator A5020245470 @default.
• W4310117770 creator A5034407018 @default.
• W4310117770 creator A5036776757 @default.
• W4310117770 creator A5037838431 @default.
• W4310117770 creator A5038524036 @default.
• W4310117770 creator A5044464086 @default.
• W4310117770 creator A5047753605 @default.
• W4310117770 creator A5048815633 @default.
• W4310117770 creator A5053979421 @default.
• W4310117770 creator A5057872518 @default.
• W4310117770 creator A5064336169 @default.
• W4310117770 creator A5070542052 @default.
• W4310117770 creator A5074529705 @default.
• W4310117770 creator A5075596275 @default.
• W4310117770 creator A5077666079 @default.
• W4310117770 creator A5083780461 @default.
• W4310117770 creator A5086214965 @default.
• W4310117770 date "2022-11-15" @default.
• W4310117770 modified "2023-10-18" @default.
• W4310117770 title "Sustained Remission and Decreased Severity of CAR T-Cell Related Adverse Events: A Pivotal Study Report of CNCT19 (inaticabtagene autoleucel) Treatment in Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-Cell ALL) in China" @default.
• W4310117770 doi "https://doi.org/10.1182/blood-2022-165002" @default.
• W4310117770 hasPublicationYear "2022" @default.
• W4310117770 type Work @default.
• W4310117770 citedByCount "0" @default.
• W4310117770 crossrefType "journal-article" @default.
• W4310117770 hasAuthorship W4310117770A5002329460 @default.
• W4310117770 hasAuthorship W4310117770A5018863416 @default.
• W4310117770 hasAuthorship W4310117770A5020245470 @default.
• W4310117770 hasAuthorship W4310117770A5034407018 @default.
• W4310117770 hasAuthorship W4310117770A5036776757 @default.
• W4310117770 hasAuthorship W4310117770A5037838431 @default.
• W4310117770 hasAuthorship W4310117770A5038524036 @default.
• W4310117770 hasAuthorship W4310117770A5044464086 @default.
• W4310117770 hasAuthorship W4310117770A5047753605 @default.
• W4310117770 hasAuthorship W4310117770A5048815633 @default.
• W4310117770 hasAuthorship W4310117770A5053979421 @default.
• W4310117770 hasAuthorship W4310117770A5057872518 @default.
• W4310117770 hasAuthorship W4310117770A5064336169 @default.
• W4310117770 hasAuthorship W4310117770A5070542052 @default.
• W4310117770 hasAuthorship W4310117770A5074529705 @default.
• W4310117770 hasAuthorship W4310117770A5075596275 @default.
• W4310117770 hasAuthorship W4310117770A5077666079 @default.
• W4310117770 hasAuthorship W4310117770A5083780461 @default.
• W4310117770 hasAuthorship W4310117770A5086214965 @default.
• W4310117770 hasConcept C121332964 @default.
• W4310117770 hasConcept C121608353 @default.
• W4310117770 hasConcept C126322002 @default.
• W4310117770 hasConcept C141071460 @default.
• W4310117770 hasConcept C142424586 @default.
• W4310117770 hasConcept C143998085 @default.
• W4310117770 hasConcept C197934379 @default.
• W4310117770 hasConcept C2776694085 @default.
• W4310117770 hasConcept C2776755627 @default.
• W4310117770 hasConcept C2777701055 @default.
• W4310117770 hasConcept C2778020697 @default.
• W4310117770 hasConcept C2778461978 @default.
• W4310117770 hasConcept C2779263901 @default.
• W4310117770 hasConcept C2780850621 @default.
• W4310117770 hasConcept C2909962599 @default.
• W4310117770 hasConcept C3875195 @default.
• W4310117770 hasConcept C71924100 @default.
• W4310117770 hasConcept C87355193 @default.
• W4310117770 hasConcept C90924648 @default.
• W4310117770 hasConceptScore W4310117770C121332964 @default.
• W4310117770 hasConceptScore W4310117770C121608353 @default.
• W4310117770 hasConceptScore W4310117770C126322002 @default.
• W4310117770 hasConceptScore W4310117770C141071460 @default.
• W4310117770 hasConceptScore W4310117770C142424586 @default.
• W4310117770 hasConceptScore W4310117770C143998085 @default.
• W4310117770 hasConceptScore W4310117770C197934379 @default.
• W4310117770 hasConceptScore W4310117770C2776694085 @default.
• W4310117770 hasConceptScore W4310117770C2776755627 @default.
• W4310117770 hasConceptScore W4310117770C2777701055 @default.
• W4310117770 hasConceptScore W4310117770C2778020697 @default.
• W4310117770 hasConceptScore W4310117770C2778461978 @default.
• W4310117770 hasConceptScore W4310117770C2779263901 @default.
• W4310117770 hasConceptScore W4310117770C2780850621 @default.
• W4310117770 hasConceptScore W4310117770C2909962599 @default.
• W4310117770 hasConceptScore W4310117770C3875195 @default.
• W4310117770 hasConceptScore W4310117770C71924100 @default.
• W4310117770 hasConceptScore W4310117770C87355193 @default.
• W4310117770 hasConceptScore W4310117770C90924648 @default.
• W4310117770 hasIssue "Supplement 1" @default.
• W4310117770 hasLocation W43101177701 @default.
• W4310117770 hasOpenAccess W4310117770 @default.
• W4310117770 hasPrimaryLocation W43101177701 @default.
• W4310117770 hasRelatedWork W2509498413 @default.
• W4310117770 hasRelatedWork W2796821082 @default.
• W4310117770 hasRelatedWork W2916176185 @default.
• W4310117770 hasRelatedWork W2931952760 @default.
• W4310117770 hasRelatedWork W2995396457 @default.
• W4310117770 hasRelatedWork W3088453061 @default.
• W4310117770 hasRelatedWork W3093575130 @default.
• W4310117770 hasRelatedWork W3097783772 @default.

• next